TRDA

Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a biotechnology company founded in 2016 and headquartered in Boston, Massachusetts. Originally incorporated as CycloPorters, Inc., the company changed its name to Entrada Therapeutics in October 2017 and went public in October 2021. Entrada focuses on developing innovative therapeutics for neuromuscular diseases using its proprietary endosomal escape vehicle (EEV) platform technology. The company represents an emerging player in the specialized field of intracellular drug delivery, targeting conditions where traditional therapies have struggled to achieve adequate cellular penetration.